bsm-60009M [Primary Antibody]
LAMP1 monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Mouse

Target Protein: LAMP1

Clonality: Monoclonal

Isotype: IgG

Entrez Gene: 3916

Swiss Prot: P11279

Source: KLH conjugated synthetic peptide derived from human LAMP1

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Lysosome associated membrane protein (LAMP1), also known as lgp120 or lgpA, is a type 1 integral membrane protein that is transported from trans Golgi networks to endosomes and then lysosomes. Upon cell activation, LAMP1 transfer to the plasma membrane is dependent on a carboxyl terminal tyrosine based motif (YXXI). Perturbation in the spacing between the tyrosine based motif relative to the membrane abolishes lysosome localization of LAMP1. This mutant protein then cycles between the plasma membrane and the endosome. Cell surface LAMP1 and LAMP2 have been shown to promote adhesion of human peripheral blood mononuclear cells (PBMC) to vascular endothelium, therefore they are possibly involved in the adhesion of PBMCs to the site of inflammation.

Size: 100ul

Concentration: 1mg/ml

Applications: WB=1:500-1000
ICC=1:50
IF=1:50

Predicted Molecular Weight: 42


Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Blocking buffer: 5% NFDM/TBST Primary ab dilution: 1:1000 Primary ab incubation condition: 2 hours at room temperature Secondary ab: Goat Anti-Rabbit IgG H&L (HRP) Lysate: HeLa, JAR Protein loading quantity: 20 μg Exposure time: 3 s Predicted MW: 45 kDa Observed MW: 110 kDa


Lane 1: Human HT-1080 cell Lysates; Lane 2: Human JAR cell Lysates; Lane 3: Human A549 cell Lysates; Lane 4: Human U-87 MG cell Lysates. Probed with LAMP1 monoclonal Antibody, unconjugated (bsm-60009M) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.